Ascendia
Xinyu Wang, Ph. D., is a seasoned scientist with extensive experience in analytical development within the pharmaceutical industry. Currently serving as a Senior Scientist at Ascendia since March 2022, Xinyu Wang has successfully developed and optimized assay and impurity methods for a 50% w/v Human Serum Albumin drug product and addressed key process challenges. Previously, Xinyu Wang held the position of Scientist at Ascendia, leading the analytical development for a lyophilized cake drug product. Prior experience as a Senior Chemist I at Tulex Pharmaceuticals involved the development of multi-stage dissolution methods and analytical techniques for various drug formulations. Xinyu Wang earned a Ph. D. in Chemistry focusing on Structural DNA Nanotechnology from New York University and a Bachelor of Engineering in Macromolecular Materials Science and Engineering from the University of Science and Technology of China.
Ascendia
1 followers
Ascendia Pharmaceuticals offers a comprehensive suite of pre-formulation for preclinical- and clinical-stage drug candidates. It specializes in improving the solubility and bioavailability of poorly water-soluble drugs using its suite of nanotechnology platforms. Ascendia formulates products for injectable, oral, and topical routes ofadministration. The company has three technology platforms - EmulSol for producing nano-emulsions, AmorSol for creating amorphous solid dispersions, and NanoSol for formulating nano-particles.